Reviewed By
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 27 Researches
7.1
USERS' SCORE
Good
Based on 3 Reviews
8.5
Supplement Facts
Serving Size: 5 Tablets
Amount Per Serving
%DV
Vitamin D3 (as cholecalciferol)
10 mcg (400 IU)
50%
Calcium (as calcium citrate)
1,000 mg
77%
Magnesium (as magnesium oxide, magnesium citrate)
500 mg
119%
Sodium
20 mg
<1%
Top Medical Research Studies
8
Magnesium scaffold shows promising results
We investigated the clinical safety and performance of a new magnesium scaffold known as DREAMS 3G. This innovative treatment aims to match the effectiveness of drug-eluting stents in coronary interventions.
Over one year, a total of 116 patients were monitored, showing promising results with minimal lumen loss and no adverse events like cardiac death or major thrombosis. Despite a few revascularization interventions, the scaffold appears to be a viable alternative.
Overall, our findings support its potential use in heart treatments.
Over one year, a total of 116 patients were monitored, showing promising results with minimal lumen loss and no adverse events like cardiac death or major thrombosis. Despite a few revascularization interventions, the scaffold appears to be a viable alternative.
Overall, our findings support its potential use in heart treatments.
9
We investigated the effects of magnesium oxide nanoparticles, created using fruit extract, on blood clotting and oxidative stress. Our experiments showed that these nanoparticles significantly extended clotting time, indicating an anticoagulant effect. They also effectively reduced damage to red blood cells and various tissues in laboratory tests, helping to restore their function. Importantly, we found these nanoparticles non-toxic, suggesting they could be a promising treatment option for oxidative stress-related conditions without adverse side effects. However, further research is needed to fully understand their potential in clinical applications.
8
We explored the connection between vitamin D levels and coronary thrombus load in patients who experienced ST-elevation myocardial infarction (STEMI). The study included 77 patients where we measured serum vitamin D levels, thrombus degree, and other relevant factors.
Our findings revealed that a concerning 79.22% of participants showed vitamin D deficiency, with those having milder thrombus loads possessing significantly higher vitamin D levels compared to those with severe thrombus loads. Moreover, as we assessed the severity of coronary artery condition, we noted that patients with higher thrombus burden also had markedly greater scores of atherosclerosis.
Importantly, we found clear negative correlations between vitamin D levels and measures of thrombus burden. Lower vitamin D levels aligned with higher TIMI frame countsāmeaning more extensive vascular obstructionāsuggesting that vitamin D might play a role in blood clot formation.
Overall, we determined that low 25(OH)D3 levels could be an independent predictor of high coronary artery thrombus load in STEMI patients. These findings highlight the potential significance of monitoring and perhaps addressing vitamin D levels in this vulnerable group.
Our findings revealed that a concerning 79.22% of participants showed vitamin D deficiency, with those having milder thrombus loads possessing significantly higher vitamin D levels compared to those with severe thrombus loads. Moreover, as we assessed the severity of coronary artery condition, we noted that patients with higher thrombus burden also had markedly greater scores of atherosclerosis.
Importantly, we found clear negative correlations between vitamin D levels and measures of thrombus burden. Lower vitamin D levels aligned with higher TIMI frame countsāmeaning more extensive vascular obstructionāsuggesting that vitamin D might play a role in blood clot formation.
Overall, we determined that low 25(OH)D3 levels could be an independent predictor of high coronary artery thrombus load in STEMI patients. These findings highlight the potential significance of monitoring and perhaps addressing vitamin D levels in this vulnerable group.
Most Useful Reviews
9
Improved calcium levels
3 people found this helpful
My child suffers from hypocalcemia, meaning poor calcium absorption in the body which led to convulsions. Doctors prescribed calcium supplements for regular use, and after trying numerous options, this one stands out for its digestibility. We conduct calcium blood tests every 3-4 months, and since starting this calcium, levels have significantly improved. We now consistently order this calcium. The tablets are easy to grind, have a pleasant taste, and my child consumes it easily in powder form with water.
9
Blood calcium improvement
1 people found this helpful
This is the best calcium! Blood tests confirmed that my calcium levels increased while I was taking these pills. The additional presence of magnesium is also a delightful bonus!
7.5
Hair loss reduction
This is the finest calcium! It has significantly reduced my hair loss and effectively raised my blood calcium levels. Additionally, it includes a small amount of magnesium to enhance calcium absorption.
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 27 Researches
7.1
- All Researches
9
We explored the effects of vitamin D3 on blood clot formation in mice lacking the klotho protein, which plays a role in regulating vitamin D3 levels. In our analysis, we focused on how klotho deficiency impacts platelet function and calcium signaling, pivotal mechanisms involved in clotting.
Our findings revealed that klotho-deficient platelets exhibited significantly reduced responses to activation, indicating that they might not form clots effectively. Specifically, we observed that calcium signaling pathways, essential for platelet activation and aggregation, were notably inhibited in these mice. The investigation utilized multiple methods, including measuring calcium levels and evaluating platelet function through various biochemical and cellular techniques.
Interestingly, when klotho-deficient mice were given a low-vitamin D diet, we discovered that their platelet function improved, suggesting a direct link between vitamin D3 levels and platelet activity. The reduced activity was associated with decreased expression of critical signaling proteins involved in calcium entry, which vitamin D3 helps regulate. Overall, our study presents evidence that vitamin D3 deficiency due to klotho absence may hinder proper blood clotting mechanisms.
Our findings revealed that klotho-deficient platelets exhibited significantly reduced responses to activation, indicating that they might not form clots effectively. Specifically, we observed that calcium signaling pathways, essential for platelet activation and aggregation, were notably inhibited in these mice. The investigation utilized multiple methods, including measuring calcium levels and evaluating platelet function through various biochemical and cellular techniques.
Interestingly, when klotho-deficient mice were given a low-vitamin D diet, we discovered that their platelet function improved, suggesting a direct link between vitamin D3 levels and platelet activity. The reduced activity was associated with decreased expression of critical signaling proteins involved in calcium entry, which vitamin D3 helps regulate. Overall, our study presents evidence that vitamin D3 deficiency due to klotho absence may hinder proper blood clotting mechanisms.
9
We evaluated the potential of vitamin D3, specifically calcitriol, in combination with other medications to prevent deep vein thrombosis (VTE) in renal transplant recipients (RTR). Focusing on how these treatments might influence the occurrence of blood clots, we followed a group of 769 RTRs over several months post-transplant.
Our findings revealed that 96 of these recipients experienced a first episode of VTE. We noticed a significant difference in rates of blood clots among those who received calcitriol alongside angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs). In fact, recipients on the combination therapy had a markedly lower rate of VTE, showing a promising 60% reduction in risk.
However, it is important to note that the isolated effect of vitamin D3 without other treatments wasn't fully determined in this study. While calcitriol showed favorable outcomes when used with blood pressure medications, further research could help clarify its individual impact on clot prevention. Overall, this research highlights the importance of collaborative strategies in managing thrombotic complications for transplant patients.
Our findings revealed that 96 of these recipients experienced a first episode of VTE. We noticed a significant difference in rates of blood clots among those who received calcitriol alongside angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs). In fact, recipients on the combination therapy had a markedly lower rate of VTE, showing a promising 60% reduction in risk.
However, it is important to note that the isolated effect of vitamin D3 without other treatments wasn't fully determined in this study. While calcitriol showed favorable outcomes when used with blood pressure medications, further research could help clarify its individual impact on clot prevention. Overall, this research highlights the importance of collaborative strategies in managing thrombotic complications for transplant patients.
9
We explored the role of calcium in promoting blood coagulation using a new zeolite-embedded regenerated cellulose aerogel (Z-RCA). This innovative hemostatic agent was designed to minimize common issues seen with previous zeolite-based products, like heat-induced tissue damage and unwanted blood clotting elsewhere in the body.
Our results showed that this aerogel effectively absorbed blood while releasing calcium ions, which play a crucial role in the blood clotting process. By combining the properties of zeolite and the calcium-releasing ability of the aerogel, we found that Z-RCA not only facilitated quicker blood clotting but did so safely, with less risk of adverse effects.
In animal trials, we observed that Z-RCA stopped bleeding faster than existing options like Quikclot and notably reduced blood loss by over 62%. This combination of effectiveness and safety makes Z-RCA a promising solution for achieving efficient hemostasis during emergencies.
Our results showed that this aerogel effectively absorbed blood while releasing calcium ions, which play a crucial role in the blood clotting process. By combining the properties of zeolite and the calcium-releasing ability of the aerogel, we found that Z-RCA not only facilitated quicker blood clotting but did so safely, with less risk of adverse effects.
In animal trials, we observed that Z-RCA stopped bleeding faster than existing options like Quikclot and notably reduced blood loss by over 62%. This combination of effectiveness and safety makes Z-RCA a promising solution for achieving efficient hemostasis during emergencies.
9
We investigated the effects of magnesium oxide nanoparticles, created using fruit extract, on blood clotting and oxidative stress. Our experiments showed that these nanoparticles significantly extended clotting time, indicating an anticoagulant effect. They also effectively reduced damage to red blood cells and various tissues in laboratory tests, helping to restore their function. Importantly, we found these nanoparticles non-toxic, suggesting they could be a promising treatment option for oxidative stress-related conditions without adverse side effects. However, further research is needed to fully understand their potential in clinical applications.
8
We focused on how 1,25-Dihydroxyvitamin D3, or vitamin D3, affects platelet aggregation, particularly in response to the SARS-CoV-2 spike protein. Individuals with COVID-19 often experience heightened blood clotting, which can lead to serious complications. Our study aimed to uncover the mechanisms behind vitamin D3ās potential benefits in reducing this risk.
Through our experiments, we discovered that vitamin D3 helped reduce platelet aggregation triggered by the spike protein. We noticed that it inhibited certain signaling pathways inside platelets, thereby curbing their ability to clump together. Even when the spike protein was introduced, vitamin D3 managed to lessen the platelet response significantly.
Interestingly, our findings suggest that vitamin D3 works by modulating a specific integrin signaling pathway, known as integrin Ī±IIbĪ²3 outside-in signaling. We observed that this process involved key proteins that play a role in platelet function. Combining vitamin D3 with a Src family kinase inhibitor showed no added benefits, indicating that vitamin D3's effects might be closely tied to these signaling pathways.
Overall, our study indicates that vitamin D3 has a beneficial role in mitigating the heightened platelet activity associated with the spike protein, offering insights into its potential use as a treatment option during COVID-19.
Through our experiments, we discovered that vitamin D3 helped reduce platelet aggregation triggered by the spike protein. We noticed that it inhibited certain signaling pathways inside platelets, thereby curbing their ability to clump together. Even when the spike protein was introduced, vitamin D3 managed to lessen the platelet response significantly.
Interestingly, our findings suggest that vitamin D3 works by modulating a specific integrin signaling pathway, known as integrin Ī±IIbĪ²3 outside-in signaling. We observed that this process involved key proteins that play a role in platelet function. Combining vitamin D3 with a Src family kinase inhibitor showed no added benefits, indicating that vitamin D3's effects might be closely tied to these signaling pathways.
Overall, our study indicates that vitamin D3 has a beneficial role in mitigating the heightened platelet activity associated with the spike protein, offering insights into its potential use as a treatment option during COVID-19.
User Reviews
USERS' SCORE
Good
Based on 3 Reviews
8.5
- All Reviews
- Positive Reviews
- Negative Reviews
9
Improved calcium levels
3 people found this helpful
My child suffers from hypocalcemia, meaning poor calcium absorption in the body which led to convulsions. Doctors prescribed calcium supplements for regular use, and after trying numerous options, this one stands out for its digestibility. We conduct calcium blood tests every 3-4 months, and since starting this calcium, levels have significantly improved. We now consistently order this calcium. The tablets are easy to grind, have a pleasant taste, and my child consumes it easily in powder form with water.
9
Blood calcium improvement
1 people found this helpful
This is the best calcium! Blood tests confirmed that my calcium levels increased while I was taking these pills. The additional presence of magnesium is also a delightful bonus!
7.5
Hair loss reduction
This is the finest calcium! It has significantly reduced my hair loss and effectively raised my blood calcium levels. Additionally, it includes a small amount of magnesium to enhance calcium absorption.
Frequently Asked Questions
9
Improved calcium levels
3 people found this helpful
My child suffers from hypocalcemia, meaning poor calcium absorption in the body which led to convulsions. Doctors prescribed calcium supplements for regular use, and after trying numerous options, this one stands out for its digestibility. We conduct calcium blood tests every 3-4 months, and since starting this calcium, levels have significantly improved. We now consistently order this calcium. The tablets are easy to grind, have a pleasant taste, and my child consumes it easily in powder form with water.
9
Blood calcium improvement
1 people found this helpful
This is the best calcium! Blood tests confirmed that my calcium levels increased while I was taking these pills. The additional presence of magnesium is also a delightful bonus!
7.5
Hair loss reduction
This is the finest calcium! It has significantly reduced my hair loss and effectively raised my blood calcium levels. Additionally, it includes a small amount of magnesium to enhance calcium absorption.
8
We focused on how 1,25-Dihydroxyvitamin D3, or vitamin D3, affects platelet aggregation, particularly in response to the SARS-CoV-2 spike protein. Individuals with COVID-19 often experience heightened blood clotting, which can lead to serious complications. Our study aimed to uncover the mechanisms behind vitamin D3ās potential benefits in reducing this risk.
Through our experiments, we discovered that vitamin D3 helped reduce platelet aggregation triggered by the spike protein. We noticed that it inhibited certain signaling pathways inside platelets, thereby curbing their ability to clump together. Even when the spike protein was introduced, vitamin D3 managed to lessen the platelet response significantly.
Interestingly, our findings suggest that vitamin D3 works by modulating a specific integrin signaling pathway, known as integrin Ī±IIbĪ²3 outside-in signaling. We observed that this process involved key proteins that play a role in platelet function. Combining vitamin D3 with a Src family kinase inhibitor showed no added benefits, indicating that vitamin D3's effects might be closely tied to these signaling pathways.
Overall, our study indicates that vitamin D3 has a beneficial role in mitigating the heightened platelet activity associated with the spike protein, offering insights into its potential use as a treatment option during COVID-19.
Through our experiments, we discovered that vitamin D3 helped reduce platelet aggregation triggered by the spike protein. We noticed that it inhibited certain signaling pathways inside platelets, thereby curbing their ability to clump together. Even when the spike protein was introduced, vitamin D3 managed to lessen the platelet response significantly.
Interestingly, our findings suggest that vitamin D3 works by modulating a specific integrin signaling pathway, known as integrin Ī±IIbĪ²3 outside-in signaling. We observed that this process involved key proteins that play a role in platelet function. Combining vitamin D3 with a Src family kinase inhibitor showed no added benefits, indicating that vitamin D3's effects might be closely tied to these signaling pathways.
Overall, our study indicates that vitamin D3 has a beneficial role in mitigating the heightened platelet activity associated with the spike protein, offering insights into its potential use as a treatment option during COVID-19.
8
We explored the connection between vitamin D levels and coronary thrombus load in patients who experienced ST-elevation myocardial infarction (STEMI). The study included 77 patients where we measured serum vitamin D levels, thrombus degree, and other relevant factors.
Our findings revealed that a concerning 79.22% of participants showed vitamin D deficiency, with those having milder thrombus loads possessing significantly higher vitamin D levels compared to those with severe thrombus loads. Moreover, as we assessed the severity of coronary artery condition, we noted that patients with higher thrombus burden also had markedly greater scores of atherosclerosis.
Importantly, we found clear negative correlations between vitamin D levels and measures of thrombus burden. Lower vitamin D levels aligned with higher TIMI frame countsāmeaning more extensive vascular obstructionāsuggesting that vitamin D might play a role in blood clot formation.
Overall, we determined that low 25(OH)D3 levels could be an independent predictor of high coronary artery thrombus load in STEMI patients. These findings highlight the potential significance of monitoring and perhaps addressing vitamin D levels in this vulnerable group.
Our findings revealed that a concerning 79.22% of participants showed vitamin D deficiency, with those having milder thrombus loads possessing significantly higher vitamin D levels compared to those with severe thrombus loads. Moreover, as we assessed the severity of coronary artery condition, we noted that patients with higher thrombus burden also had markedly greater scores of atherosclerosis.
Importantly, we found clear negative correlations between vitamin D levels and measures of thrombus burden. Lower vitamin D levels aligned with higher TIMI frame countsāmeaning more extensive vascular obstructionāsuggesting that vitamin D might play a role in blood clot formation.
Overall, we determined that low 25(OH)D3 levels could be an independent predictor of high coronary artery thrombus load in STEMI patients. These findings highlight the potential significance of monitoring and perhaps addressing vitamin D levels in this vulnerable group.
2
Vitamin D treatment shows no benefit
In our exploration of how vitamin D might affect blood clotting, we conducted a pilot randomized clinical trial involving 40 patients diagnosed with either deep vein thrombosis or pulmonary embolism. These individuals were vitamin D deficient, which is already known to contribute to the development of blood clots.
We divided the patients into two groups: one received a high dose of vitamin Dā50,000 IU weekly for eight weeks followed by less frequent dosesāwhile the control group did not receive any vitamin D. After one and three months, we measured levels of two key biomarkers related to blood clotting: P-selectin and hs-CRP.
We discovered that there was no significant decrease in either biomarker in both groups over the study period. This suggests that treating vitamin D deficiency doesnāt meaningfully impact these specific markers of thrombosis in patients with clotting issues.
However, we did find something interesting. Those who received vitamin D treatment appeared to manage their anticoagulant therapy with warfarin more effectively, using lower doses of the medication. While our initial hypothesis about vitamin Dās direct effect on blood clot markers didnāt hold, this potential interaction with warfarin is intriguing and warrants further investigation in larger studies to better understand the relationship between vitamin D and blood clotting.
We divided the patients into two groups: one received a high dose of vitamin Dā50,000 IU weekly for eight weeks followed by less frequent dosesāwhile the control group did not receive any vitamin D. After one and three months, we measured levels of two key biomarkers related to blood clotting: P-selectin and hs-CRP.
We discovered that there was no significant decrease in either biomarker in both groups over the study period. This suggests that treating vitamin D deficiency doesnāt meaningfully impact these specific markers of thrombosis in patients with clotting issues.
However, we did find something interesting. Those who received vitamin D treatment appeared to manage their anticoagulant therapy with warfarin more effectively, using lower doses of the medication. While our initial hypothesis about vitamin Dās direct effect on blood clot markers didnāt hold, this potential interaction with warfarin is intriguing and warrants further investigation in larger studies to better understand the relationship between vitamin D and blood clotting.
4
Calcium and vitamin D3 impact on VTE
We aimed to understand how vitamin D3, when combined with calcium, might affect the risk of developing blood clots, also known as venous thromboembolism (VTE). In a notable study involving over 36,000 postmenopausal women aged between 50 to 79, participants were randomly assigned to receive either daily supplements of 1,000 mg of calcium and 400 IU of vitamin D3 or a placebo. This rigorous double-blind, placebo-controlled design lasted an average of seven years, ensuring that neither the participants nor the researchers knew who was receiving the active treatment.
Our analysis looked closely at the rates of VTE between those taking the supplements and those on the placebo. We found that there was no significant difference in the overall incidence of VTE between the two groupsā320 events in the supplement group versus 348 in the placebo group. This translates to a hazard ratio of 0.92, suggesting that the combined supplementation did not lower the risk of blood clots for these generally healthy women.
Interestingly, while the overall risk didnāt change, we observed a noticeable reduction in the risk of idiopathic VTE (where thereās no clear cause) among women who took calcium and vitamin D3, with 40 events compared to 65 in the placebo group. This finding may call for deeper investigation, as it hints at a potential benefit that could be worth exploring further.
To sum up, regular supplementation with calcium and vitamin D3 does not seem to reduce the overall risk of blood clots in postmenopausal women. However, our observation of a lower risk for idiopathic blood clots in the treatment group offers a glimmer of hope for future studies on this topic.
Our analysis looked closely at the rates of VTE between those taking the supplements and those on the placebo. We found that there was no significant difference in the overall incidence of VTE between the two groupsā320 events in the supplement group versus 348 in the placebo group. This translates to a hazard ratio of 0.92, suggesting that the combined supplementation did not lower the risk of blood clots for these generally healthy women.
Interestingly, while the overall risk didnāt change, we observed a noticeable reduction in the risk of idiopathic VTE (where thereās no clear cause) among women who took calcium and vitamin D3, with 40 events compared to 65 in the placebo group. This finding may call for deeper investigation, as it hints at a potential benefit that could be worth exploring further.
To sum up, regular supplementation with calcium and vitamin D3 does not seem to reduce the overall risk of blood clots in postmenopausal women. However, our observation of a lower risk for idiopathic blood clots in the treatment group offers a glimmer of hope for future studies on this topic.
References
- Wang R, Tian Z, Wang C, Zhang B, Zhu M, et al. 1,25-Dihydroxyvitamin D3 attenuates platelet aggregation potentiated by SARS-CoV-2 spike protein via inhibiting integrin Ī±IIbĪ²3 outside-in signaling. Cell Biochem Funct. 2024;42:e4039. 10.1002/cbf.4039
- Uguz B, Oztas S, Zengin I, Topal D, Tiryakioglu SK, et al. Relationship between vitamin D deficiency and thrombus load in patients with ST-elevation myocardial infarction. Eur Rev Med Pharmacol Sci. 2022;26:7015. 10.26355/eurrev_202210_29885
- Hejazi ME, Modarresi-Ghazani F, Hamishehkar H, Mesgari-Abbasi M, Dousti S, et al. The Effect of Treatment of Vitamin D Deficiency on the Level of P-Selectin and hs-CRP in Patients With Thromboembolism: A Pilot Randomized Clinical Trial. J Clin Pharmacol. 2017;57:40. 10.1002/jcph.774
- Blondon M, Rodabough RJ, Budrys N, Johnson KC, Berger JS, et al. The effect of calcium plus vitamin D supplementation on the risk of venous thromboembolism. From the Women's Health Initiative Randomized Controlled Trial. Thromb Haemost. 2015;113:999. 10.1160/TH14-05-0478
- Gholami K, Talasaz AH, Entezari-Maleki T, Salarifar M, Hadjibabaie M, et al. The Effect of High-Dose Vitamin D3 on Soluble P-Selectin and hs-CRP Level in Patients With Venous Thromboembolism: A Randomized Clinical Trial. Clin Appl Thromb Hemost. 2016;22:483. 10.1177/1076029614568715
- Borst O, MĆ¼nzer P, Schmid E, Schmidt EM, Russo A, et al. 1,25(OH)2 vitamin D3-dependent inhibition of platelet Ca2+ signaling and thrombus formation in klotho-deficient mice. FASEB J. 2014;28:2108. 10.1096/fj.13-239277
- Moscarelli L, Zanazzi M, Bertoni E, Caroti L, Rosso G, et al. Renin angiotensin system blockade and activated vitamin D as a means of preventing deep vein thrombosis in renal transplant recipients. Clin Nephrol. 2011;75:440.
- Jorde R, Sneve M, Torjesen P, Figenschau Y, Hansen JB. Parameters of the thrombogram are associated with serum 25-hydroxyvitamin D levels at baseline, but not affected during supplementation with vitamin D. Thromb Res. 2010;125:e210. 10.1016/j.thromres.2009.12.011
- Wu-Wong JR. Are vitamin D receptor activators useful for the treatment of thrombosis?. Curr Opin Investig Drugs. 2009;10:919.
- Jin Z, Chen L, Liu X, Xia R, Li W, et al. Zeolite firmly anchored regenerated cellulose aerogel for efficient and biosafe hemostasis. Int J Biol Macromol. 2025;304:140743. 10.1016/j.ijbiomac.2025.140743
- Tran VA, Griffin EM, Elliott JD, Scholl RL, Hill RB, et al. Thrombotic Complications Associated With Right Atrial Lines in Neonates and Infants Undergoing Cardiac Surgery. Is Calcium Chloride a Culprit?. J Cardiothorac Vasc Anesth. 2025. 10.1053/j.jvca.2025.01.008
- Kim J, Kim M, Lee CS, Choi EY. Sufficient Magnesium Intake Reduces Retinal Vein Occlusion Risk: National Health and Nutrition Examination Survey Analysis. Nutrients. 2025;17. 10.3390/nu17071285
- Guo X, Zeng X, He Y, Zhang X, Shi W, et al. An Antibacterial, Antioxidant Adherent Sponge Constructed for Control of Arterial Bleeding Via Gallic Acid-Mediated Robust Assembly of Fibrous Clay in Collagen. ACS Appl Mater Interfaces. 2025;17:16489. 10.1021/acsami.4c19209
- MĆ¼ller M, Ludwig L, Englert H, Riedl KA, MĆ¼ller MC, et al. A novel stent flow chamber system demonstrates reduced thrombogenicity of bioresorbable magnesium scaffolds. Sci Rep. 2024;14:26691. 10.1038/s41598-024-77266-0
- Zhang J, Chen Z, Rao L, He Y. Coronary bioresorbable metallic stents: Advancements and future perspectives. J Cardiol. 2025;85:69. 10.1016/j.jjcc.2024.08.003
- WÅodarczak A, Rola P, WÅodarczak S, Szudrowicz M, Giniewicz K, et al. Two-Year Outcomes for Patients with Non-ST-Elevation Acute Coronary Syndrome Treated with Magmaris and Absorb Bioresorbable Scaffolds in Large-Vessel Lesions. J Pers Med. 2024;14. 10.3390/jpm14050540
- Galli S, Troiano S, Palloshi A, Rapetto C, Pisano F, et al. Comparison of acute versus stable coronary syndrome in patients treated with the Magmaris scaffold: Two-year results from the Magmaris Multicenter Italian Registry. Cardiovasc Revasc Med. 2023;57:53. 10.1016/j.carrev.2023.06.022
- WÅodarczak A, Rola P, Barycki M, Furtan Å, Åanocha M, et al. Mid-term safety and efficacy of magnesium bioresorbable vascular scaffolds - magmaris in diabetic population. 2-Years outcome in acute coronary syndrome cohort. Diab Vasc Dis Res. 2023;20:14791641231188705. 10.1177/14791641231188705
- Gotru SK, Mammadova-Bach E, Sogkas G, Schuhmann MK, Schmitt K, et al. MAGT1 Deficiency Dysregulates Platelet Cation Homeostasis and Accelerates Arterial Thrombosis and Ischemic Stroke in Mice. Arterioscler Thromb Vasc Biol. 2023;43:1494. 10.1161/ATVBAHA.122.318115
- Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, et al. A new resorbable magnesium scaffold for de novo coronary lesions (DREAMS 3): one-year results of the BIOMAG-I first-in-human study. EuroIntervention. 2023;19:e414. 10.4244/EIJ-D-23-00326
- Wlodarczak A, Montorsi P, Torzewski J, Bennett J, Starmer G, et al. One- and two-year clinical outcomes of treatment with resorbable magnesium scaffolds for coronary artery disease: the prospective, international, multicentre BIOSOLVE-IV registry. EuroIntervention. 2023;19:232. 10.4244/EIJ-D-22-01069
- Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, et al. Safety and performance of the third-generation drug-eluting resorbable coronary magnesium scaffold system in the treatment of subjects with de novo coronary artery lesions: 6-month results of the prospective, multicenter BIOMAG-I first-in-human study. EClinicalMedicine. 2023;59:101940. 10.1016/j.eclinm.2023.101940
- Pompei G, Campo G, Ruggiero R, Maffeo D, Sgura F, et al. Long-term outcomes of patients treated with sirolimus-eluting resorbable magnesium scaffolds: Insights from the SHERPA-MAGIC study. Int J Cardiol. 2023;383:1. 10.1016/j.ijcard.2023.04.029
- Fedele G, Castiglioni S, Maier JAM, Locatelli L. The Effects of Sirolimus and Magnesium on Primary Human Coronary Endothelial Cells: An In Vitro Study. Int J Mol Sci. 2023;24. 10.3390/ijms24032930
- Tonai K, Katayama S, Koyama K, Sata N, Tomioka Y, et al. Association between hypomagnesemia and coagulopathy in sepsis: a retrospective observational study. BMC Anesthesiol. 2022;22:359. 10.1186/s12871-022-01903-2
- Seguchi M, Aytekin A, Lenz T, Nicol P, Alvarez-Covarrubias HA, et al. Challenges of the newer generation of resorbable magnesium scaffolds: Lessons from failure mechanisms of the past generation. J Cardiol. 2023;81:179. 10.1016/j.jjcc.2022.09.003
- Venkatappa MM, Udagani C, Hanumegowda SM, Pramod SN, Venkataramaiah S, et al. Effect of Biofunctional Green Synthesized MgO-Nanoparticles on Oxidative-Stress-Induced Tissue Damage and Thrombosis. Molecules. 2022;27. 10.3390/molecules27165162
